BioCryst Pharmaceuticals Inc (MEX:BCRX)
MXN 155 0 (0%) Market Cap: 32.99 Bil Enterprise Value: 42.75 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 10:00PM GMT
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference today with BioCryst. We're going to do a Q&A session with the management team right after this. It's just down the hall in the Yorkshire Room, so you can follow me over there if you want to hear more. But for the presentation, I'm going to turn it over to the company's CEO, Jon Stonehouse.

Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Director

Thank you, Jess. Thanks for the invite to this year's J.P. Morgan Healthcare Conference, and good afternoon.

I'm going to be making some forward-looking statements. Those statements have risks and our risk factors can be found on our website listed on the bottom of Slide 2.

So what makes us different at BioCryst is bringing forward oral drugs for patients with rare disease. When I -- when we first started talking about this, I thought of it as some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot